Multiple Myeloma Day
Multiple Myeloma is
DelveInsight Blog
Trending:
EMA to review Cidara Therapeutics’ Rezafun...
Aug 23, 2022
EU Regulator Starts its Review of Cidara Therapeutics’ Candidiasis Therapy Rezafungin The EU regulator has begun its ...
Novartis’ Canakinumab for NSCLC; Novartis’...
Aug 16, 2022
Novartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were alrea...
AstraZeneca’s Imfinzi Shows Positive Resul...
Jul 05, 2022
FDA Grants Orphan Drug Designation to Evorpacept for AML ALX Oncology Holdings announced that the U.S. Food and Drug ...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epid...
Dystrophic epidermolysis bullosa (DEB) is a common skin disease with a chronic history ...
Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis...
Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 ...
Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment
Bronchopulmonary Dysplasia is the most common long-term respiratory morbidity of low-we...
A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment
Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landsc...
NexoBrid and its Awaiting US Approval
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
RECENT ARTICLES
-Agonist.png "Toll-like Receptors Agonist")
